Beleaguered Biogen faces the music as a chorus of critics push for a transformative approach to M&A

Credit Suisse has decided to start offering Biogen crisis analysis, and it’s adding an influential voice backing some major changes at the bellwether biotech.

“Nothing will come of nothing,” its analysts headlined in their first review of the company, pointing straight at the disastrous Phase III failure of aducanumab that has severely damaged Biogen’s market valuation.